MannKind Corporation (MNKD): Price and Financial Metrics

MannKind Corporation (MNKD): $4.41

0.11 (+2.56%)

POWR Rating

Component Grades













Add MNKD to Watchlist
Sign Up

Industry: Biotech


of 504

in industry


  • MNKD scores best on the Quality dimension, with a Quality rank ahead of 44.58% of US stocks.
  • MNKD's strongest trending metric is Value; it's been moving down over the last 52 weeks.
  • MNKD ranks lowest in Sentiment; there it ranks in the 3rd percentile.

MNKD Stock Summary

  • Mannkind Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 5% of US listed stocks.
  • MNKD's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 5% of US stocks.
  • With a year-over-year growth in debt of 131.17%, Mannkind Corp's debt growth rate surpasses 93.04% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Mannkind Corp, a group of peers worth examining would be CLS, TNET, SANM, ATEC, and DRQ.
  • Visit MNKD's SEC page to see the company's official filings. To visit the company's web site, go to

MNKD Valuation Summary

  • MNKD's price/earnings ratio is -13.9; this is 138.08% lower than that of the median Healthcare stock.
  • Over the past 208 months, MNKD's price/sales ratio has gone NA NA.
  • Over the past 208 months, MNKD's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for MNKD.

Stock Date P/S P/B P/E EV/EBIT
MNKD 2021-08-31 16.1 -6.5 -13.9 -19.8
MNKD 2021-08-30 15.8 -6.4 -13.7 -19.5
MNKD 2021-08-27 16.5 -6.7 -14.2 -20.1
MNKD 2021-08-26 15.5 -6.3 -13.4 -19.2
MNKD 2021-08-25 15.4 -6.3 -13.3 -19.1
MNKD 2021-08-24 14.9 -6.0 -12.9 -18.5

MNKD Growth Metrics

  • Its 3 year price growth rate is now at -78.03%.
  • Its 5 year net income to common stockholders growth rate is now at 87.42%.
  • Its 4 year price growth rate is now at -80%.
Over the past 30 months, MNKD's revenue has gone up $46,652,000.

The table below shows MNKD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 74.511 -47.403 -86.105
2021-03-31 66.345 -29.64 -60.834
2020-12-31 65.144 -28.128 -57.24
2020-09-30 62.694 -33.47 -45.092
2020-06-30 61.937 -72.061 -44.207
2020-03-31 61.825 -88.105 -46.342

MNKD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • MNKD has a Quality Grade of C, ranking ahead of 46.43% of graded US stocks.
  • MNKD's asset turnover comes in at 0.384 -- ranking 124th of 681 Pharmaceutical Products stocks.
  • VERU, PLX, and LGND are the stocks whose asset turnover ratios are most correlated with MNKD.

The table below shows MNKD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.384 0.611 -0.321
2021-03-31 0.424 0.627 -0.330
2020-12-31 0.673 0.622 -0.564
2020-09-30 0.673 0.595 -0.391
2020-06-30 0.666 0.529 -0.297
2020-03-31 0.705 0.516 -0.324

MNKD Price Target

For more insight on analysts targets of MNKD, see our MNKD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $6.17 Average Broker Recommendation 1.33 (Strong Buy)

MNKD Stock Price Chart Interactive Chart >

Price chart for MNKD

MNKD Price/Volume Stats

Current price $4.41 52-week high $6.25
Prev. close $4.30 52-week low $1.93
Day low $4.30 Volume 2,482,500
Day high $4.42 Avg. volume 4,147,242
50-day MA $4.63 Dividend yield N/A
200-day MA $4.37 Market Cap 1.10B

MannKind Corporation (MNKD) Company Bio

MannKind Corporation focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. The company was founded in 1991 and is based in Valencia, California.

MNKD Latest News Stream

Event/Time News Detail
Loading, please wait...

MNKD Latest Social Stream

Loading social stream, please wait...

View Full MNKD Social Stream

Latest MNKD News From Around the Web

Below are the latest news stories about Mannkind Corp that investors may wish to consider to help them evaluate MNKD as an investment opportunity.

United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

Yahoo | October 19, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | October 18, 2021

MNKD Stock: The Disappointing FDA News That Has MannKind Shares Diving Today

MannKind (MNKD) stock is taking a beating on Monday after releasing an update to investors concerning news from the FDA for Tyvaso DPI.

William White on InvestorPlace | October 18, 2021

The FuelCell Energy Chatter That Has FCEL Stock Trending Today

FuelCell Energy (FCEL) stock is on the move Monday despite a lack of news concerning the fuel cell development and manufacturing company.

William White on InvestorPlace | October 18, 2021

Upcoming IPOs This Week: Vita Coco, Portillo’s and 8 More New Stocks to Watch

There's upcoming IPOs this week that traders are going to want to keep an eye on and we're helping out with a handy list for investors.

William White on InvestorPlace | October 18, 2021

Read More 'MNKD' Stories Here

MNKD Price Returns

1-mo -5.36%
3-mo 0.92%
6-mo -5.77%
1-year 110.00%
3-year 139.67%
5-year 49.49%
YTD 40.89%
2020 142.64%
2019 21.70%
2018 -54.31%
2017 -27.50%
2016 -55.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8548 seconds.